Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This clinical study will test the efficacy and safety of nicotinamide for lupus-associated
skin lesions refractory to the treatment of hydroxychloroquine plus low-dose corticosteroids
in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE).
Phase:
Phase 2
Details
Lead Sponsor:
Second Xiangya Hospital of Central South University
Collaborators:
Hunan Provincial Natural Science Foundation of China National Key Clinical Specialty Construction Project of China National Natural Science Foundation of China